Hepatitis D screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (41 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis D}} | {{Hepatitis D}} | ||
{{CMG}}; {{ | {{CMG}}; {{AE}} {{JS}} {{JM}} | ||
==Overview== | |||
The general population, with low risk of [[HBV]] and [[HDV]] infection does not need to be screened. However, individuals known to be [[HBsAg]] positive, with acute or chronic [[hepatitis]], or those [[HBsAg]] negative, but who are [[IgM]] anti-HBc positive, should be screened for [[HDV]]. [[Blood]] products should also be screened in order to avoid [[transmission]] of the virus through [[blood transfusion]]s or [[hemodialysis]]. | |||
==Screening== | ==Screening== | ||
The following groups of patients should be screened for hepatitis D: | |||
*Patients known to be [[HBsAg]] positive, who have acute or chronic hepatitis | |||
*Patients who have acute hepatitis B, who are not [[HBsAg]] positive and who are [[IgM]] anti-HBc positive | |||
The general population, without risk for [[HBV]] and [[HDV]] does not need to be [[screening|screened]]. | |||
Blood products should also be screened for the presence of [[HDV]] and [[HBV]], in order to prevent infection by [[blood transfusion]] and [[hemodialysis]].<ref name="pmid21511329">{{cite journal| author=Hughes SA, Wedemeyer H, Harrison PM| title=Hepatitis delta virus. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 73-85 | pmid=21511329 | doi=10.1016/S0140-6736(10)61931-9 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21511329 }} </ref> | |||
For recommendations regarding HBV and HCC screening, refer to [[Hepatitis B screening]]<ref name="pmid15229781">{{cite journal |author=Lok AS, McMahon BJ |title=[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines] |journal=[[Romanian Journal of Gastroenterology]] |volume=13 |issue=2 |pages=150–4 |year=2004 |month=June |pmid=15229781 |doi= |url=http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdf |accessdate=2012-02-10}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Hepatitis|D]] | [[Category:Hepatitis|D]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
[[Category:Disease]] | |||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Hepatology]] | ||
[[Category:Gastroenterology]] | |||
Latest revision as of 22:06, 29 July 2020
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D screening On the Web |
|
American Roentgen Ray Society Images of Hepatitis D screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]
Overview
The general population, with low risk of HBV and HDV infection does not need to be screened. However, individuals known to be HBsAg positive, with acute or chronic hepatitis, or those HBsAg negative, but who are IgM anti-HBc positive, should be screened for HDV. Blood products should also be screened in order to avoid transmission of the virus through blood transfusions or hemodialysis.
Screening
The following groups of patients should be screened for hepatitis D:
- Patients known to be HBsAg positive, who have acute or chronic hepatitis
- Patients who have acute hepatitis B, who are not HBsAg positive and who are IgM anti-HBc positive
The general population, without risk for HBV and HDV does not need to be screened.
Blood products should also be screened for the presence of HDV and HBV, in order to prevent infection by blood transfusion and hemodialysis.[1]
For recommendations regarding HBV and HCC screening, refer to Hepatitis B screening[2]
References
- ↑ Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
- ↑ Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter
|month=ignored (help)